Hepatera Release: Maxwell Biotech Venture Fund’s Portfolio Company Hepatera Recruits First Patients in Phase 1b/2a Clinical Trial of Myrcludex B for HBV

Published: Dec 12, 2012

MOSCOW--(BUSINESS WIRE)--Hepatera, a Russian biotech company and part of Maxwell Biotech Venture Fund’s portfolio, has announced today the inclusion of the first three patients with chronic hepatitis B in the clinical trial phase Ib-IIa of Myrcludex B. Hepatera was founded in 2011 and is focused on the development of innovative therapeutics for the treatment of liver diseases. The study is being conducted in major Russian specialized clinical centers and its results are expected in the end of 2013.

Back to news